Italia markets open in 1 hour 48 minutes
Dow Jones
35.258,61 -36,15 (-0,10%) Nasdaq
15.021,81 +124,47 (+0,84%) Nikkei 225
29.191,63 +166,17 (+0,57%) EUR/USD
1,1650 +0,0031 (+0,27%) BTC-EUR
53.538,77 -439,58 (-0,81%) CMC Crypto 200
1.457,03 +5,39 (+0,37%)
Onxeo SA (0NWK.L)
LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a portafoglio
1,2790+0,5485 (+75,09%)
Alla chiusura: 6:00PM BST
| Chiusura precedente | 0,7305 |
| Aperto | 0,5530 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,5530 - 0,5530 |
| Intervallo di 52 settimane | 0,5530 - 0,5530 |
| Volume | 1.000 |
| Media Volume | N/D |
| Capitalizzazione | 72,269M |
| Beta (5 anni mensile) | 1,49 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,1230 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare Sector
Dr Robert L. Coleman, Chief Scientific Officer of US Oncology Network and Dr Jacques Mallet, former SVP Portfolio Analytics/Corporate Strategy at Sanofi, join the Company’s Board as independent members Paris (France), Oct. 14, 2021 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), « Onxeo », a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, today announced the a
© 2021 Verizon Media. Tutti i diritti riservati.
